Opioids News and Research RSS Feed - Opioids News and Research

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.
Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology. [More]
Using multiple pharmacies to fill prescriptions associated with opioid overdoses

Using multiple pharmacies to fill prescriptions associated with opioid overdoses

A study conducted in the state of Washington and reported in The Journal of Pain showed that almost half of deaths attributed to prescription opioids were Medicaid recipients, and using multiple pharmacies to fill prescriptions is linked with opioid overdoses. [More]
1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

1 in 4 people with histories of nicotine use, substance abuse likely to use opioid painkillers long-term

Opioid painkiller addiction and accidental overdoses have become far too common across the United States. To try to identify who is most at risk, Mayo Clinic researchers studied how many patients prescribed an opioid painkiller for the first time progressed to long-term prescriptions. The answer: 1 in 4. People with histories of tobacco use and substance abuse were likeliest to use opioid painkillers long-term. [More]
Educational messages about naloxone's lifesaving benefits can bolster support for its use

Educational messages about naloxone's lifesaving benefits can bolster support for its use

While most Americans do not support policies designed to increase distribution of naloxone - a medication that reverses the effects of a drug overdose - certain types of educational messages about its lifesaving benefits may bolster support for its use, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]

Egalet reports top-line results from Category 3 HAL study of Egalet-002

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare. [More]

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
Adding tamper resistant properties to medications can help curb prescription drug abuse

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations. [More]
Opioid offers pain relief for Parkinson’s patients

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows. [More]
Veterans who died from drug overdoses also prescribed benzodiazepines for pain

Veterans who died from drug overdoses also prescribed benzodiazepines for pain

In a recent study, nearly half of all veterans who died from drug overdoses while prescribed opioids for pain were also receiving benzodiazepines, or benzos, which are common medications for the treatment of anxiety, insomnia and alcohol withdrawal. Veterans prescribed higher doses of benzodiazepines while concurrently receiving opioids were at greater risk of overdose death than those on lower doses of benzodiazepines. [More]
US physicians with waivers increase potential access to effective medication-assisted treatment

US physicians with waivers increase potential access to effective medication-assisted treatment

American physicians with waivers allowing them to provide office-based medication-assisted buprenorphine treatment to patients addicted to opioids were able to increase potential access to effective medication-assisted treatment by 74 percent from 2002 to 2011, according to a new RAND Corporation study. [More]
Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

A variety of factors including questions about risk and reluctance to offend patients limits clinician willingness to prescribe a potentially life-saving medication that counteracts the effects of an opioid overdose, according to a Kaiser Permanente Colorado study published today in the Journal of General Internal Medicine. [More]
Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps that include the consistent use of experienced medical teams for a single type of surgery, preemptive antibiotics before the procedure, less reliance on potent opioids during recovery and urging patients to get out of bed and move around sooner can not only prevent infections, blood clots and other serious complications in people undergoing colorectal operations, but can also accelerate recovery and reduce cost of care, according to results of an ongoing program at The Johns Hopkins Hospital. [More]
Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn reports positive topline results from Probuphine Phase 3 study for treatment of opioid addiction

Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. [More]

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]

Category 1 findings support robust abuse-deterrent features of Egalet-002 for management of severe pain

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
US patients undergoing orthopaedic surgery receive more treatments for pain

US patients undergoing orthopaedic surgery receive more treatments for pain

New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally. [More]
BioDelivery Sciences calls for new treatment options for opioid addiction

BioDelivery Sciences calls for new treatment options for opioid addiction

As the rate of opioid abuse soars to new levels, growing recognition of the problem is garnering unprecedented media attention—as well as motivating innovative new approaches to better treatment. [More]
Study points to the importance of addressing health-related needs of ex-prisoners

Study points to the importance of addressing health-related needs of ex-prisoners

Ex-prisoners with a history of risky drug use, mental illness or poverty are more likely to end up back behind bars. Those who are obese, are chronically ill or have attempted suicide are more likely to remain in the community. These are some of the findings from an exploratory study into health-related factors that could be used to predict whether a person released from prison will end up in custody again. [More]
Canadian researchers shed light on molecular dynamics of chronic pain

Canadian researchers shed light on molecular dynamics of chronic pain

Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain. [More]
Advertisement
Advertisement